Cash from Investing (Quarterly) Chart

Historical Cash from Investing (Quarterly) Data

View and export this data back to 2007. Start Trial.
Date Value
September 30, 2026 10.25M
June 30, 2026 8.214M
March 31, 2026 -2.114M
December 31, 2025 8.147M
September 30, 2025 -26.20M
June 30, 2025 9.232M
March 31, 2025 6.622M
December 31, 2024 5.039M
September 30, 2024 -5.535M
June 30, 2024 4.673M
March 31, 2024 4.208M
December 31, 2023 6.392M
September 30, 2023 1.184M
June 30, 2023 -28.22M
March 31, 2023 2.509M
December 31, 2022 4.371M
September 30, 2022 1.970M
June 30, 2022 2.509M
March 31, 2022 2.214M
December 31, 2021 -8.630M
September 30, 2021 -12.79M
June 30, 2021 1.004M
March 31, 2021 -0.009M
December 31, 2020 0.4203M
September 30, 2020 -14.27M
Date Value
June 30, 2020 2.541M
March 31, 2020 -5.301M
December 31, 2019 1.025M
September 30, 2019 2.938M
June 30, 2019 3.037M
March 31, 2019 -10.93M
December 31, 2018
September 30, 2018 -0.0205M
June 30, 2018 -0.0096M
March 31, 2018 -0.032M
December 31, 2017 -0.0149M
September 30, 2017 -0.0042M
June 30, 2017 -0.0028M
March 31, 2017 0.00
December 31, 2016
September 30, 2016 -0.0023M
June 30, 2016 -0.0033M
March 31, 2016 0.0027M
December 31, 2015 -0.0025M
September 30, 2015 -0.0011M
June 30, 2015 0.0003M
March 31, 2015 -0.0022M
December 31, 2014 0.0014M
September 30, 2014 -0.005M
June 30, 2014 -0.0115M

Cash From Investing Definition

Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.

Read full definition.

Cash from Investing (Quarterly) Range, Past 5 Years

View Cash from Investing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Investing (Quarterly) Benchmarks

View Cash from Investing (Quarterly) Benchmarks
Start Trial
Arrowhead Pharmaceuticals, Inc. 203.86M
Nektar Therapeutics 66.90M
Fortress Biotech, Inc. -0.007M
ACADIA Pharmaceuticals, Inc. -86.15M
Alnylam Pharmaceuticals, Inc. -311.74M